<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551599</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-016</org_study_id>
    <nct_id>NCT04551599</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Food and Age on Danicopan</brief_title>
  <official_title>A Two-Part, Open-Label Phase 1 Study to Evaluate the Effect of Food and Age on the Pharmacokinetics of Danicopan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, 2-part study. Part 1 will be a randomized, 2-sequence, 2-period&#xD;
      crossover, food-effect study in healthy young adult participants. Part 2 will be a 1-period&#xD;
      age-effect study in healthy elderly male participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover study, and Part 2 will be a 1-period study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To Maximum Observed Concentration (Tmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Of Danicopan Under Fed Conditions In Healthy Elderly Males</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf Of Danicopan Under Fed Conditions In Healthy Elderly Males</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Of Danicopan Under Fed Conditions In Healthy Elderly Males</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Of Danicopan Under Fed Conditions In Healthy Elderly Males</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Healthy Young Adults And Healthy Elderly Males With Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up (10 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, young, adult participants will receive danicopan once each Period as follows:&#xD;
Period 1: Danicopan administered under fed conditions.&#xD;
Period 2: Danicopan administered under fasted conditions.&#xD;
There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, young, adult participants will receive danicopan once each Period as follows:&#xD;
Period 1: Danicopan administered under fasted conditions.&#xD;
Period 2: Danicopan administered under fed conditions.&#xD;
There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>A single dose of danicopan (200 milligrams) will be administered orally.</description>
    <arm_group_label>Part 1: Sequence 1</arm_group_label>
    <arm_group_label>Part 1: Sequence 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>ACH-0144471</other_name>
    <other_name>ALXN2040</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Young adult males or females, between 18 and 55 years of age (Part 1 only).&#xD;
&#xD;
          2. Elderly male participants aged ≥ 65 years of age at screening (Part 2 only).&#xD;
&#xD;
          3. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at screening.&#xD;
&#xD;
          4. No clinically significant history or presence of electrocardiogram findings at&#xD;
             screening.&#xD;
&#xD;
          5. Non-sterile male participants must agree to abstinence or use a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
          6. Female participants of childbearing potential must either agree to abstinence or to&#xD;
             use, with their male partner, a highly effective method of contraception (Part 1&#xD;
             only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          2. Pregnant or lactating (Part 1 only).&#xD;
&#xD;
          3. History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          4. History or presence of drug or alcohol abuse within previous 2 years, current tobacco&#xD;
             user, and positive drugs-of-abuse or alcohol screen at screening or Day -1 of Period&#xD;
             1.&#xD;
&#xD;
          5. History of meningococcal infection, or a first-degree relative with a history of&#xD;
             meningococcal infection.&#xD;
&#xD;
          6. Body temperature ≥ 38.0°Celsius at screening or prior to (first) dosing in Period 1 or&#xD;
             history of febrile illness, or other evidence of infection, within 14 days prior to&#xD;
             (first) dosing.&#xD;
&#xD;
          7. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          8. A history of significant multiple and/or severe allergies or has had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          9. Major surgery within previous 4 weeks.&#xD;
&#xD;
         10. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             (first) dosing, whichever is longer.&#xD;
&#xD;
         11. Donation of whole blood from 3 months prior to (first) dosing or of plasma from 30&#xD;
             days before (first) dosing, receipt of blood products within 6 months prior to (first)&#xD;
             dosing, or receipt of a vaccine within 30 days prior to (first) dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Complement</keyword>
  <keyword>Danicopan</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food-effect</keyword>
  <keyword>Age-effect</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

